NA
GMAB icon

NewEdge Advisors’s Genmab GMAB Stock Holding History

NewEdge Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95K Hold
71
– – ﹤0.01% 3918
2026
Q1 		$1.91K Hold
71
– – ﹤0.01% 3820
2025
Q4 		$2.19K Sell
71
-1,165
-94% -$36.3K ﹤0.01% 3870
2025
Q3 		$37.9K Buy
1,236
+1,143
+1,229% +$27.9K ﹤0.01% 2917
2025
Q2 		$1.92K Sell
93
-11,443
-99% -$235K ﹤0.01% 3627
2025
Q1 		$226K Sell
11,536
-7,768
-40% -$163K ﹤0.01% 2043
2024
Q4 		$403K Buy
19,304
+2,171
+13% +$47.7K ﹤0.01% 1685
2024
Q3 		$418K Buy
17,133
+1,767
+11% +$47.2K ﹤0.01% 1580
2024
Q2 		$386K Buy
15,366
+14,291
+1,329% +$405K ﹤0.01% 1571
2024
Q1 		$32.2K Sell
1,075
-310
-22% -$9.11K ﹤0.01% 2455
2023
Q4 		$44.1K Buy
1,385
+711
+105% +$22.3K ﹤0.01% 2269
2023
Q3 		$23.8K Buy
674
+80
+13% +$3.05K ﹤0.01% 2338
2023
Q2 		$22.6K Sell
594
-2,406
-80% -$95.9K ﹤0.01% 2350
2023
Q1 		$113K Buy
3,000
+110
+4% +$4.23K ﹤0.01% 1705
2022
Q4 		$5.33K Buy
+2,890
New +$119K ﹤0.01% 2568

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NewEdge Advisors's GMAB Position: Q2 2026 in Review

NewEdge Advisors held its Genmab (GMAB) position steady in Q2 2026 at 71 shares worth $1.95K. The position accounts for ﹤0.01% of the portfolio, ranked #3918.

NewEdge Advisors first reported a position in GMAB in Q4 2022 and has held it in 15 quarters since. The position peaked at $418K in Q3 2024. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • NewEdge Advisors held 71 shares of Genmab worth $1.95K as of Q2 2026.
  • NewEdge Advisors left its Genmab share count unchanged in Q2 2026.
  • Genmab made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3918 holding.
  • NewEdge Advisors first reported a position in Genmab in Q4 2022 and has held it in 15 quarters since.
  • NewEdge Advisors's Genmab position peaked at $418K in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.